| Summary of Revenue by Geographic Areas and Segment |
The following tables summarize revenue by segment and region for the periods presented (in thousands): | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, 2026 | | TriLink | | Cygnus | | Total | | North America | $ | 24,646 | | $ | 6,638 | | $ | 31,284 | | Europe, the Middle East and Africa | 6,129 | | 4,324 | | 10,453 | | Asia Pacific | 3,701 | | 5,618 | | 9,319 | | Latin and Central America | 193 | | 193 | | 386 | | Total revenue | $ | 34,669 | | $ | 16,773 | | $ | 51,442 |
| | | | | | | | | | | | | | | | | | | Six Months Ended June 30, 2026 | | TriLink | | Cygnus | | Total | | North America | $ | 52,599 | | $ | 14,374 | | $ | 66,973 | | Europe, the Middle East and Africa | 23,660 | | 8,740 | | 32,400 | | Asia Pacific | 5,610 | | 11,581 | | 17,191 | | Latin and Central America | 276 | | 439 | | 715 | | Total revenue | $ | 82,145 | | $ | 35,134 | | $ | 117,279 |
| | | | | | | | | | | | | | | | | | | Three Months Ended June 30, 2025 | | TriLink | | Cygnus | | Total | | North America | $ | 23,872 | | $ | 6,767 | | $ | 30,639 | | Europe, the Middle East and Africa | 4,107 | | 4,288 | | 8,395 | | Asia Pacific | 3,023 | | 5,135 | | 8,158 | | Latin and Central America | 83 | | 122 | | 205 | | Total revenue | $ | 31,085 | | $ | 16,312 | | $ | 47,397 | | | | | | | | Six Months Ended June 30, 2025 | | TriLink | | Cygnus | | Total | | North America | $ | 45,846 | | $ | 14,062 | | $ | 59,908 | | Europe, the Middle East and Africa | 6,701 | | 8,572 | | 15,273 | | Asia Pacific | 7,170 | | 11,545 | | 18,715 | | Latin and Central America | 118 | | 233 | | 351 | | Total revenue | $ | 59,835 | | $ | 34,412 | | $ | 94,247 |
|
| Summary of Fair Value of Assets Measured on Recurring Basis |
The following tables summarize the Company’s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy as of the periods presented (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Fair Value Measurements as of June 30, 2026 | | Line Item in the Condensed Consolidated Balance Sheets | | Level 1 | | Level 2 | | Level 3 | | Total | | Assets | | | | | | | | | | Money market funds | Cash and cash equivalents | | $ | 69,165 | | | $ | — | | | $ | — | | | $ | 69,165 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Fair Value Measurements as of December 31, 2025 | | Line Item in the Condensed Consolidated Balance Sheets | | Level 1 | | Level 2 | | Level 3 | | Total | | Assets | | | | | | | | | | Money market funds | Cash and cash equivalents | | $ | 216,384 | | | $ | — | | | $ | — | | | $ | 216,384 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
| Summary of Concentration of Revenue |
The following table summarizes revenue from each of our customers who individually accounted for 10% or more of our total revenue or accounts receivable for the periods presented: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Revenue | | Accounts Receivable, net | | Three Months Ended
June 30, | | Six Months Ended
June 30, | | June 30, 2026 | | December 31, 2025 | | 2026 | | 2025 | | 2026 | | 2025 | | | | Pfizer, Inc. | * | | * | | 12.2 | % | | * | | * | | * | | Nacalai USA, Inc. | * | | * | | * | | * | | * | | 12.0 | % | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Seqirus Inc. | * | | * | | * | | * | | 18.3 | % | | * |
____________________ *Less than 10%
|